Related Experiment Videos
[Intermittent peritoneal dialysis: a 6 years' experience]
Revista Medica De Chile
|September 1, 1989
Summary
Intermittent Peritoneal Dialysis (IPD) is a safe and effective treatment for end-stage renal disease (ESRD). This study found IPD well-tolerated, with satisfactory clinical outcomes and comparable infection rates in diabetic and non-diabetic patients.
Area of Science:
- Nephrology
- Internal Medicine
Background:
- End-stage renal disease (ESRD) requires renal replacement therapy.
- Intermittent Peritoneal Dialysis (IPD) offers an alternative treatment modality.
Purpose of the Study:
- To evaluate the experience, results, and complications of Intermittent Peritoneal Dialysis (IPD) in ESRD patients.
- To assess the safety and efficacy of IPD, particularly in diabetic patients.
Main Methods:
- A cohort of 28 ESRD patients (24 adults, 4 children) were treated with IPD between 1981-1988.
- Included 8 diabetic patients with diabetic nephropathy.
- Treatment duration ranged from 3 to 36 months.
Main Results:
- IPD was well-tolerated with satisfactory extracellular volume control, hematocrit, plasma protein, acid-base balance, nutritional status, and uremic toxin levels.
- Diabetic patients showed statistically significant differences in Na+, alkaline phosphatases, glucose, and glycosylated hemoglobin levels.
- Peritonitis rates were low (0.065-0.074 peritonitis/patient-month), with Gram-negative bacteria, Staphylococcus aureus, and Staphylococcus epidermidis as common causative agents. Survival curves were similar for diabetic and non-diabetic groups.
Conclusions:
- IPD is a viable and safe therapeutic option for ESRD patients.
- Diabetic ESRD patients can safely undergo IPD without an increased infection rate compared to non-diabetic patients.